Department of Gastrointestinal Surgery, Tianjin First Central Hospital, No.24 Fukang Road, Nankai District, Tianjin, 300190, People's Republic of China.
Clin Transl Oncol. 2024 Jan;26(1):297-307. doi: 10.1007/s12094-023-03259-6. Epub 2023 Jun 27.
The purpose of this study was to explore the appropriate surgical procedure and clinical decision for appendiceal adenocarcinoma.
A total of 1,984 appendiceal adenocarcinoma patients from 2004 to 2015 were retrospectively identified from the Surveillance, Epidemiology, and End Results (SEER) database. All patients were divided into three groups based on the extent of surgical resection: appendectomy (N = 335), partial colectomy (N = 390) and right hemicolectomy (N = 1,259). The clinicopathological features and survival outcomes of three groups were compared, and independent prognostic factors were assessed.
The 5-year OS rates of patients who underwent appendectomy, partial colectomy and right hemicolectomy were 58.3%, 65.5% and 69.1%, respectively (right hemicolectomy vs appendectomy, P < 0.001; right hemicolectomy vs partial colectomy, P = 0.285; partial colectomy vs appendectomy, P = 0.045). The 5-year CSS rates of patients who underwent appendectomy, partial colectomy and right hemicolectomy were 73.2%, 77.0% and 78.7%, respectively (right hemicolectomy vs appendectomy, P = 0.046; right hemicolectomy vs partial colectomy, P = 0.545; partial colectomy vs appendectomy, P = 0.246). The subgroup analysis based on the pathological TNM stage indicated that there was no survival difference amongst three surgical procedures for stage I patients (5-year CSS rate: 90.8%, 93.9% and 98.1%, respectively). The prognosis of patients who underwent an appendectomy was poorer than that of those who underwent partial colectomy (5-year OS rate: 53.5% vs 67.1%, P = 0.005; 5-year CSS rate: 65.2% vs 78.7%, P = 0.003) or right hemicolectomy (5-year OS rate: 74.2% vs 53.23%, P < 0.001; 5-year CSS rate: 65.2% vs 82.5%, P < 0.001) for stage II disease. Right hemicolectomy did not show a survival advantage over partial colectomy for stage II (5-year CSS, P = 0.255) and stage III (5-year CSS, P = 0.846) appendiceal adenocarcinoma.
Right hemicolectomy may not always be necessary for appendiceal adenocarcinoma patients. An appendectomy could be sufficient for therapeutic effect of stage I patients, but limited for stage II patients. Right hemicolectomy was not superior to partial colectomy for advanced stage patients, suggesting omission of standard hemicolectomy might be feasible. However, adequate lymphadenectomy should be strongly recommended.
本研究旨在探讨阑尾腺癌的适宜手术方式和临床决策。
本研究回顾性分析了 2004 年至 2015 年间来自 SEER 数据库的 1984 例阑尾腺癌患者。所有患者均根据手术切除范围分为三组:阑尾切除术(N=335)、部分结肠切除术(N=390)和右半结肠切除术(N=1259)。比较三组患者的临床病理特征和生存结局,并评估独立预后因素。
阑尾切除术、部分结肠切除术和右半结肠切除术患者的 5 年 OS 率分别为 58.3%、65.5%和 69.1%(右半结肠切除术 vs 阑尾切除术,P<0.001;右半结肠切除术 vs 部分结肠切除术,P=0.285;部分结肠切除术 vs 阑尾切除术,P=0.045)。阑尾切除术、部分结肠切除术和右半结肠切除术患者的 5 年 CSS 率分别为 73.2%、77.0%和 78.7%(右半结肠切除术 vs 阑尾切除术,P=0.046;右半结肠切除术 vs 部分结肠切除术,P=0.545;部分结肠切除术 vs 阑尾切除术,P=0.246)。基于病理 TNM 分期的亚组分析表明,对于Ⅰ期患者,三种手术方式的生存无差异(5 年 CSS 率分别为 90.8%、93.9%和 98.1%)。与部分结肠切除术(5 年 OS 率:53.5% vs 67.1%,P=0.005;5 年 CSS 率:65.2% vs 78.7%,P=0.003)或右半结肠切除术(5 年 OS 率:74.2% vs 53.23%,P<0.001;5 年 CSS 率:65.2% vs 82.5%,P<0.001)相比,行阑尾切除术的Ⅱ期患者的预后较差。对于Ⅱ期(5 年 CSS,P=0.255)和Ⅲ期(5 年 CSS,P=0.846)阑尾腺癌患者,右半结肠切除术与部分结肠切除术相比,并未显示出生存优势。
对于阑尾腺癌患者,不一定需要行右半结肠切除术。对于Ⅰ期患者,阑尾切除术可能足以达到治疗效果,但对于Ⅱ期患者则不够。对于晚期患者,右半结肠切除术并不优于部分结肠切除术,提示标准的半结肠切除术可能是可行的,但是强烈推荐进行充分的淋巴结清扫。